AEs, adverse events; AIH, Autoimmune Hepatitis; ALP, Alkaline Phosphatase; AMA, Antimitochondrial antibodies; BZF, Bezafibrate; CKD, chronic kidney disease; Elafibranor; FDA, Food and Drug; FF, Fenofibrate; FXR, Farnesoid X Receptor; Fibrates; GGT, γ-glutamil transferase; HCC, Hepatocellular Carcinoma; HDL, high-density lipoprotein; HR, Hazard Ratio; HSC, Hepatic Stellate Cells; IL-1ß, Interleukin-1; IgM, Immunoglobulin M; LDL, low-density- lipoprotein; LT, Liver Transplant; MDR3, multidrug resistance protein 3; NASH, Non Alcoholic Steato-Hepatits; NRS, Numerical Raing Scale; OCA, Obeticholic Acid; OR, Odds Ratio; PAR, protease-activated receptors; PBC, Primary Biliary Cholangitis; PC, phosphatidylcholine; PH, Portal Hypertension; PPAR agonists; PPAR, peroxisome proliferator-activated receptor; Primary biliary cholangitis; QoL, Quality of Life; RCT, randomized controlled trial; SAE, Severe Adverse Event; Saroglitazar; Seladelpar; TGR, transmembrane G protein-coupled receptor; TLR, Toll Like Receptor; TNF-α, Tumor Necrosis Factor- α; UDCA; UDCA, ursodeoxycholic acid; UK, United Kingdom; ULN, upper limit of normal; VAS, Visual Analogue Scale; VRS, Verbal Rating Scale